iRhythm Technologies, Inc. Logo

iRhythm Technologies, Inc.

IRTC

(0.8)
Stock Price

90,39 USD

-14.33% ROA

-127.85% ROE

-14.25x PER

Market Cap.

1.880.100.859,00 USD

665.76% DER

0% Yield

-26.9% NPM

iRhythm Technologies, Inc. Stock Analysis

iRhythm Technologies, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

iRhythm Technologies, Inc. Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

2 DER

The stock has a reasonable amount of debt compared to its ownership (60%), suggesting a balanced financial position and a moderate level of risk.

3 ROE

The stock's ROE indicates a negative return (-46.35%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-23.9%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's elevated P/BV ratio (11.34x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-455) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

iRhythm Technologies, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

iRhythm Technologies, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

iRhythm Technologies, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

iRhythm Technologies, Inc. Revenue
Year Revenue Growth
2013 15.368.000
2014 21.749.000 29.34%
2015 36.140.000 39.82%
2016 64.072.000 43.59%
2017 98.509.000 34.96%
2018 147.293.000 33.12%
2019 214.552.000 31.35%
2020 265.166.000 19.09%
2021 322.825.000 17.86%
2022 410.921.000 21.44%
2023 498.416.000 17.55%
2023 492.681.000 -1.16%
2024 592.188.000 16.8%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

iRhythm Technologies, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2013 3.664.000
2014 5.698.000 35.7%
2015 6.349.000 10.25%
2016 7.150.000 11.2%
2017 13.335.000 46.38%
2018 20.750.000 35.73%
2019 37.299.000 44.37%
2020 41.329.000 9.75%
2021 38.671.000 -6.87%
2022 46.610.000 17.03%
2023 65.236.000 28.55%
2023 60.244.000 -8.29%
2024 78.760.000 23.51%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

iRhythm Technologies, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 0
2014 0 0%
2015 0 0%
2016 51.621.000 100%
2017 84.737.000 39.08%
2018 131.582.000 35.6%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

iRhythm Technologies, Inc. EBITDA
Year EBITDA Growth
2013 -11.028.000
2014 -14.816.000 25.57%
2015 -21.248.000 30.27%
2016 -17.655.000 -20.35%
2017 -26.034.000 32.18%
2018 -42.092.000 38.15%
2019 -52.860.000 20.37%
2020 -42.082.000 -25.61%
2021 -99.825.000 57.84%
2022 -85.140.000 -17.25%
2023 -81.732.000 -4.17%
2023 -91.939.000 11.1%
2024 -66.324.000 -38.62%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

iRhythm Technologies, Inc. Gross Profit
Year Gross Profit Growth
2013 6.522.000
2014 11.158.000 41.55%
2015 21.440.000 47.96%
2016 43.189.000 50.36%
2017 70.801.000 39%
2018 108.714.000 34.87%
2019 162.067.000 32.92%
2020 194.889.000 16.84%
2021 213.567.000 8.75%
2022 281.632.000 24.17%
2023 329.896.000 14.63%
2023 331.806.000 0.58%
2024 413.884.000 19.83%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

iRhythm Technologies, Inc. Net Profit
Year Net Profit Growth
2013 -13.589.000
2014 -15.832.000 14.17%
2015 -22.799.000 30.56%
2016 -20.903.000 -9.07%
2017 -29.420.000 28.95%
2018 -48.280.000 39.06%
2019 -54.568.000 11.52%
2020 -43.830.000 -24.5%
2021 -101.361.000 56.76%
2022 -116.155.000 12.74%
2023 -108.464.000 -7.09%
2023 -123.406.000 12.11%
2024 -80.428.000 -53.44%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

iRhythm Technologies, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 -11
2014 -1 -900%
2015 -2 0%
2016 -4 66.67%
2017 -1 -200%
2018 -2 50%
2019 -2 0%
2020 -2 -100%
2021 -3 66.67%
2022 -4 0%
2023 -4 0%
2023 -4 25%
2024 -3 -100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

iRhythm Technologies, Inc. Free Cashflow
Year Free Cashflow Growth
2013 -12.301.000
2014 -16.165.000 23.9%
2015 -19.792.000 18.33%
2016 -19.414.000 -1.95%
2017 -18.473.000 -5.09%
2018 -34.248.000 46.06%
2019 -42.320.000 19.07%
2020 -27.310.000 -54.96%
2021 -65.820.000 58.51%
2022 -52.842.000 -24.56%
2023 -90.525.000 41.63%
2023 -7.891.000 -1047.19%
2024 3.352.000 335.41%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

iRhythm Technologies, Inc. Operating Cashflow
Year Operating Cashflow Growth
2013 -11.849.000
2014 -15.626.000 24.17%
2015 -18.005.000 13.21%
2016 -16.651.000 -8.13%
2017 -14.911.000 -11.67%
2018 -29.068.000 48.7%
2019 -21.863.000 -32.96%
2020 -13.759.000 -58.9%
2021 -37.753.000 63.56%
2022 -23.012.000 -64.06%
2023 -50.101.000 54.07%
2023 1.196.000 4289.05%
2024 11.840.000 89.9%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

iRhythm Technologies, Inc. Capital Expenditure
Year Capital Expenditure Growth
2013 452.000
2014 539.000 16.14%
2015 1.787.000 69.84%
2016 2.763.000 35.32%
2017 3.562.000 22.43%
2018 5.180.000 31.24%
2019 20.457.000 74.68%
2020 13.551.000 -50.96%
2021 28.067.000 51.72%
2022 29.830.000 5.91%
2023 40.424.000 26.21%
2023 9.087.000 -344.86%
2024 8.488.000 -7.06%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

iRhythm Technologies, Inc. Equity
Year Equity Growth
2013 4.600.000
2014 -80.544.000 105.71%
2015 -101.624.000 20.74%
2016 92.562.000 209.79%
2017 79.553.000 -16.35%
2018 54.422.000 -46.18%
2019 135.409.000 59.81%
2020 341.612.000 60.36%
2021 279.515.000 -22.22%
2022 239.812.000 -16.56%
2023 210.097.000 -14.14%
2023 219.795.000 4.41%
2024 99.189.000 -121.59%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

iRhythm Technologies, Inc. Assets
Year Assets Growth
2013 13.263.000
2014 18.509.000 28.34%
2015 37.872.000 51.13%
2016 138.156.000 72.59%
2017 133.123.000 -3.78%
2018 119.710.000 -11.2%
2019 306.212.000 60.91%
2020 511.739.000 40.16%
2021 462.967.000 -10.53%
2022 448.222.000 -3.29%
2023 433.144.000 -3.48%
2023 439.769.000 1.51%
2024 919.185.000 52.16%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

iRhythm Technologies, Inc. Liabilities
Year Liabilities Growth
2013 8.663.000
2014 99.053.000 91.25%
2015 139.496.000 28.99%
2016 45.594.000 -205.95%
2017 53.570.000 14.89%
2018 65.288.000 17.95%
2019 170.803.000 61.78%
2020 170.127.000 -0.4%
2021 183.452.000 7.26%
2022 208.410.000 11.98%
2023 223.047.000 6.56%
2023 219.974.000 -1.4%
2024 819.996.000 73.17%

iRhythm Technologies, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
17.24
Net Income per Share
-4.23
Price to Earning Ratio
-14.25x
Price To Sales Ratio
3.5x
POCF Ratio
-34.11
PFCF Ratio
-19.62
Price to Book Ratio
18.9
EV to Sales
3.85
EV Over EBITDA
-22.85
EV to Operating CashFlow
-37.59
EV to FreeCashFlow
-21.56
Earnings Yield
-0.07
FreeCashFlow Yield
-0.05
Market Cap
1,88 Bil.
Enterprise Value
2,07 Bil.
Graham Number
17.4
Graham NetNet
-5.99

Income Statement Metrics

Net Income per Share
-4.23
Income Quality
0.42
ROE
-0.85
Return On Assets
-0.17
Return On Capital Employed
-0.17
Net Income per EBT
1
EBT Per Ebit
1.07
Ebit per Revenue
-0.25
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.13
Stock Based Compensation to Revenue
0.16
Gross Profit Margin
0.68
Operating Profit Margin
-0.25
Pretax Profit Margin
-0.27
Net Profit Margin
-0.27

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.76
Free CashFlow per Share
-3.08
Capex to Operating CashFlow
-0.74
Capex to Revenue
0.08
Capex to Depreciation
1.65
Return on Invested Capital
-0.15
Return on Tangible Assets
-0.14
Days Sales Outstanding
58.11
Days Payables Outstanding
27.81
Days of Inventory on Hand
31.95
Receivables Turnover
6.28
Payables Turnover
13.13
Inventory Turnover
11.42
Capex per Share
1.31

Balance Sheet

Cash per Share
18,03
Book Value per Share
3,18
Tangible Book Value per Share
3.16
Shareholders Equity per Share
3.18
Interest Debt per Share
21.46
Debt to Equity
6.66
Debt to Assets
0.72
Net Debt to EBITDA
-2.06
Current Ratio
6.92
Tangible Asset Value
0,10 Bil.
Net Current Asset Value
-0,14 Bil.
Invested Capital
744880000
Working Capital
0,58 Bil.
Intangibles to Total Assets
0
Average Receivables
0,09 Bil.
Average Payables
0,01 Bil.
Average Inventory
15149000
Debt to Market Cap
0.35

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

iRhythm Technologies, Inc. Dividends
Year Dividends Growth

iRhythm Technologies, Inc. Profile

About iRhythm Technologies, Inc.

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

CEO
Mr. Quentin S. Blackford
Employee
2.000
Address
699 8th Street
San Francisco, 94103

iRhythm Technologies, Inc. Executives & BODs

iRhythm Technologies, Inc. Executives & BODs
# Name Age
1 Mr. Patrick Michael Murphy J.D.
Chief Business & Legal Officer
70
2 Mr. Mervin Smith
Executive Vice President of Business Operations
70
3 Mr. Chad M. Patterson
Chief Commercial Officer
70
4 Ms. Stephanie Zhadkevich
Director of Investor Relations
70
5 Dr. Minang P. Turakhia M.D., M.S.
Chief Medical & Scientific Officer and Executive Vice President of Product Innovation
70
6 Mr. Marc Rosenbaum
Senior Vice President of Finance & Chief Accounting Officer
70
7 Mr. Daniel G. Wilson
Executive Vice President of Corporate Development & Investor Relations
70
8 Mr. Quentin S. Blackford
President, Chief Executive Officer & Director
70
9 Ms. Sumi Shrishrimal
Executive Vice President & Chief Risk Officer
70

iRhythm Technologies, Inc. Competitors

CONMED Corporation Logo
CONMED Corporation

CNMD

(1.5)
LivaNova PLC Logo
LivaNova PLC

LIVN

(2.2)
Heska Corporation Logo
Heska Corporation

HSKA

(1.0)
NeuroPace, Inc. Logo
NeuroPace, Inc.

NPCE

(0.5)
Electromed, Inc. Logo
Electromed, Inc.

ELMD

(2.0)
Surmodics, Inc. Logo
Surmodics, Inc.

SRDX

(0.8)
Glaukos Corporation Logo
Glaukos Corporation

GKOS

(0.5)
Paragon 28, Inc. Logo
Paragon 28, Inc.

FNA

(1.5)
NuVasive, Inc. Logo
NuVasive, Inc.

NUVA

(1.0)
Bruker Corporation Logo
Bruker Corporation

BRKR

(2.5)